Skip to main content
Daily Report

Daily Ards Research Analysis

11/23/2025
3 papers selected
3 analyzed

Among ARDS-focused studies, a prospective ICU cohort using processed EEG found that many paralyzed patients on continuous neuromuscular blockade may be inadequately sedated and that propofol plus midazolam achieves deeper sedation than single agents. A retrospective ECMO study in COVID-19 ARDS showed marked d-dimer reductions and platelet/LDH improvements after circuit exchanges, supporting d-dimer trends as a trigger for elective replacement. A narrative review synthesizes current practice for

Summary

Among ARDS-focused studies, a prospective ICU cohort using processed EEG found that many paralyzed patients on continuous neuromuscular blockade may be inadequately sedated and that propofol plus midazolam achieves deeper sedation than single agents. A retrospective ECMO study in COVID-19 ARDS showed marked d-dimer reductions and platelet/LDH improvements after circuit exchanges, supporting d-dimer trends as a trigger for elective replacement. A narrative review synthesizes current practice for ECMO in severe trauma, highlighting survival differences between VV and VA ECMO and the need for trauma-specific decision tools.

Research Themes

  • Brain-focused sedation monitoring in ARDS under neuromuscular blockade
  • ECMO circuit management and coagulation biomarkers (d-dimer) in COVID-19 ARDS
  • ECMO utilization and outcomes in severe trauma (VV vs VA) with complications and prognostic tools

Selected Articles

1. Sedation Depth in Acute Respiratory Distress Syndrome Patients Receiving Neuromuscular Blockade: A Prospective Observational Study.

72.5Level IICohort
Journal of cardiothoracic and vascular anesthesia · 2025PMID: 41274845

In a 60-patient prospective ICU cohort of ARDS under continuous NMBA, processed EEG revealed that half had PSI >50 and 16.7% had PSI >75, suggesting potentially inadequate sedation despite continuous infusion. Combined propofol plus midazolam achieved lower PSI than single agents, and PSI/SEF declined over the first 24 hours.

Impact: This study highlights a high prevalence of potential under-sedation in paralyzed ARDS, challenging assumptions of adequate sedation during NMBA and supporting brain-focused monitoring.

Clinical Implications: Consider adjunctive pEEG to titrate sedation in ARDS patients receiving continuous NMBA, and recognize that propofol plus midazolam may help achieve deeper sedation when clinically appropriate.

Key Findings

  • 50% had PSI >50 and 16.7% had PSI >75 despite continuous sedation under NMBA
  • Propofol plus midazolam achieved significantly lower PSI than single-agent regimens (p < 0.001)
  • PSI and SEF decreased significantly from baseline across 24 hours (overall p < 0.001), with no hemodynamic differences between groups

Methodological Strengths

  • Prospective design with repeated pEEG measurements at seven predefined time points
  • Objective brain monitoring metrics (PSI, bilateral SEF) with statistical testing across time and regimens

Limitations

  • Single-center observational study without randomization; sample size of 60 limits generalizability
  • Awareness was not directly assessed; pEEG thresholds for clinically relevant outcomes remain to be validated

Future Directions: Randomized trials testing pEEG-guided sedation targets in ARDS under NMBA, evaluating awareness, delirium, ventilator synchrony, and outcomes.

OBJECTIVE: The primary objective of this study was to evaluate sedation depth using processed electroencephalography (pEEG) in adults with acute respiratory distress syndrome (ARDS) receiving continuous neuromuscular blockade (NMBA). SECONDARY OBJECTIVES INCLUDED: (1) to estimate the prevalence of potential inadequate and excessive sedation; (2) to describe 24-hour temporal trends in Patient State Index (PSI) and spectral edge frequency (SEF; right [SEF-R] and left [SEF-L]) (T0-T24); and (3) to explore associations with sedative regimens. DESIGN: Prospective observational study. SETTING: Tertiary intensive care unit (ICU). PARTICIPANTS: Sixty adult patients with ARDS receiving continuous NMBA infusions for at least 24 hours. INTERVENTIONS: Sedation was achieved with propofol and/or midazolam, with fentanyl used as an analgesic adjunct. pEEG monitoring was applied using PSI, SEF-R, and SEF-L. MEASUREMENTS AND MAIN RESULTS: PSI, SEF-R, and SEF-L values were recorded at seven time points over 24 hours (T0-T24). PSI values were categorized as deep (<25), adequate (25-50), and potentially inadequate (>50) sedation. The median PSI value was 53.3; 50% of patients had a PSI >50, and 16.7% had a PSI >75, indicating potentially inadequate sedation despite continuous infusion. No significant hemodynamic differences were observed between adequately and inadequately sedated patients. Patients receiving propofol plus midazolam had significantly lower PSI values compared with those in the single-agent groups (p < 0.001). Across predefined time points (T0-T24), PSI decreased significantly from T0 to subsequent time points (overall p < 0.001), and SEF-R and SEF-L also showed significant time effects; pairwise comparisons involving T0 were consistently significant (see Supplementary Table 1). CONCLUSIONS: Among paralyzed ICU patients receiving NMBA, a substantial proportion demonstrated indices consistent with potential inadequate sedation despite standard protocols; explicit awareness was not assessed. pEEG monitoring should be interpreted cautiously and as an adjunct to clinical assessment, it may provide real-time information to support individualized, brain-focused sedation management.

2. Haemostatic changes following ECMO circuit replacement in adult patients with COVID-19: An exploratory retrospective study.

61Level IIICohort
Thrombosis research · 2025PMID: 41273900

In 48 COVID-19 ARDS patients on VV-ECMO, 96 circuit exchanges were analyzed and showed a significant drop in d-dimer (median 19 to 4 μg/ml), increased platelets, and decreased LDH, with fibrinogen unchanged. Pre-exchange d-dimer surges correlated with post-exchange reductions, supporting d-dimer trends as a trigger for elective circuit replacement.

Impact: Identifies a practical, quantifiable biomarker (d-dimer trend) to guide ECMO circuit exchange, potentially standardizing a high-stakes decision with direct relevance to ARDS care.

Clinical Implications: Trend d-dimer closely during VV-ECMO for COVID-19 ARDS; rapid rises may prompt consideration of elective circuit replacement alongside clinical and circuit performance indicators.

Key Findings

  • D-dimer decreased significantly from 19 to 4 μg/ml by day 3 post-exchange (p < 0.001)
  • Platelet counts increased (p = 0.024) and LDH levels decreased (p = 0.001) after exchange, while fibrinogen did not change
  • Pre-exchange d-dimer surges correlated with post-exchange decreases (R = -0.66, p < 0.001)

Methodological Strengths

  • Objective laboratory endpoints with clear pre- and post-exchange comparisons across 96 exchanges
  • Correlation analysis linking pre-exchange d-dimer rises to post-exchange decreases

Limitations

  • Retrospective, single-center study with potential confounding by indication for exchange
  • Short-term biomarker outcomes without direct linkage to clinical endpoints (e.g., survival, bleeding, thromboembolism)

Future Directions: Prospective multicenter studies to define d-dimer thresholds and integrate clinical/circuit performance metrics, assessing safety, outcomes, and cost-effectiveness of exchange strategies.

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is an important intervention for severe respiratory failure, yet coagulation abnormalities and circuit thrombosis remain significant challenges. Circuit exchanges are frequently performed to restore oxygenator function and mitigate ECMO-related coagulopathies, but optimal criteria for their indication remain unclear. METHODS: This retrospective analysis included adult patients with coronavirus disease 2019 associated acute respiratory distress syndrome (ARDS) receiving venovenous (VV) ECMO at a tertiary hospital between January 2020 and April 2023. The primary endpoint was the change in d-dimer level on the third day after a circuit exchange compared to the last value before the circuit exchange. Secondary analyses included parameters such as fibrinogen, platelet count, LDH, post‑oxygenator pO RESULTS: Among 48 patients, 37 (77.1 %) underwent at least one coagulation-related circuit exchange, totalling 96 exchanges. D-dimer levels significantly decreased from 19 μg/ml (IQR 11-25) before exchange to 4 μg/ml (IQR 2-7) after exchange (p < 0.001). Platelet counts increased significantly (p = 0.024), while LDH levels decreased (p = 0.001). No significant changes were observed in fibrinogen levels. A sharp increase in d-dimer prior to exchange correlated with subsequent decreases post-exchange (R = -0.66, p < 0.001). CONCLUSIONS: ECMO circuit exchanges are associated with significant improvements in coagulation parameters, particularly d-dimer reduction, suggesting that d-dimer trends may serve as a key indicator for elective circuit replacement. Future prospective studies should refine exchange criteria to optimize patient outcomes while minimizing unnecessary interventions.

3. Challenges of ECMO use for severe trauma: a narrative review.

33Level VSystematic Review
Hereditas · 2025PMID: 41275312

This narrative review synthesizes indications, outcomes, and complications of ECMO in severe trauma. VV-ECMO is mainly used for trauma-associated ARDS with higher reported survival than VA-ECMO; major complications include infection, hemorrhage, and thrombosis, underscoring the need for trauma-specific decision tools and standardized protocols.

Impact: Provides an integrated view across modes (VV vs VA), conditions (trauma ARDS, cardiogenic shock, ECPR), and prognostic tools, highlighting gaps where prospective trauma-specific studies are needed.

Clinical Implications: For trauma patients requiring ECMO, preferentially consider VV-ECMO for isolated respiratory failure and VA-ECMO for shock/arrest; anticipate infection, bleeding, and thrombosis risks, and use severity scores while advocating development of trauma-specific tools.

Key Findings

  • VV-ECMO is primarily used for trauma-associated ARDS with reported survival of 72.3%, compared to 39.0% for VA-ECMO
  • Major complications include infection, hemorrhage, and thrombosis requiring coordinated prevention and management
  • Existing prognostic tools (NISS, SAPS III, SOFA) are used, but trauma-specific decision models are lacking and RCT data are limited

Methodological Strengths

  • Comprehensive literature search spanning 2000–2025 across multiple source types
  • Synthesis across ECMO modes and trauma phenotypes with pragmatic clinical focus

Limitations

  • Narrative (non-systematic) review without PRISMA methodology; potential selection and publication bias
  • Lack of randomized controlled trial data limits causal inference and standardized recommendations

Future Directions: Develop trauma-specific decision tools and standardized anticoagulation/infection control protocols; conduct multicenter prospective studies to refine indications and prognostication.

BACKGROUND: Patients with severe trauma are at high risk of developing life-threatening complications, including acute respiratory failure and circulatory collapse. Extracorporeal membrane oxygenation (ECMO) offers critical support when conventional therapies fail. This narrative review aimed to analyze the clinical application of ECMO in patients with severe trauma, focusing on indications, complications, prognostic factors, and future directions. METHODS: A comprehensive literature search was conducted to identify studies published between January 2000 and April 2025. Sources included original research articles, systematic reviews, and meta-analyses, supplemented by relevant clinical guidelines and expert consensus statements pertaining to ECMO use in trauma care. RESULTS: Veno-venous ECMO has been primarily utilized in patients with trauma-associated acute respiratory distress syndrome, while veno-arterial ECMO has been employed in the management of cardiogenic shock and cardiac arrest. Reported survival rates were 72.3% for veno-venous ECMO and 39.0% for veno-arterial ECMO. ECMO has also been used in patients with traumatic brain injury and those undergoing extracorporeal cardiopulmonary resuscitation, although randomized controlled trial data remain limited Major complications include infection, hemorrhage, and thrombosis, which require coordinated prevention and management strategies. Prognostic tools such as the New Injury Severity Score, Simplified Acute Physiology Score III, and Sequential Organ Failure Assessment score are used in clinical evaluation, though trauma-specific models are still lacking. CONCLUSION: ECMO offers a supportive treatment modality in the management of patients with severe trauma. To improve clinical outcomes, further development of trauma-specific decision tools, multicenter studies, and standardized protocols for anticoagulation and infection control is necessary to support individualized care.